NMDA receptor modulators and uses thereof

US11807650B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• David R. Anderson · Salem, US
• Robert A. Volkmann · Mystic, US
• Frank S. Menniti · Mystic, US
• Christopher Fanger · Bolton, US
• Yuelian Xu · Zhejiang, CN

Key dates

• Filing date: Jan 27, 2022
• Grant date: Nov 7, 2023
• Expiry date: Feb 6, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/20
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.